These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 18334657)

  • 41. Clinical aspects of inflammatory bowel disease.
    Siegmund B; Zeitz M
    Eur J Immunol; 2009 Aug; 39(8):2026-30. PubMed ID: 19672897
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The genetics and immunopathogenesis of inflammatory bowel disease.
    Cho JH
    Nat Rev Immunol; 2008 Jun; 8(6):458-66. PubMed ID: 18500230
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Inflammatory bowel disease.
    Beglinger C
    Swiss Med Wkly; 2009 Sep; 139(37-38):526. PubMed ID: 19852078
    [No Abstract]   [Full Text] [Related]  

  • 44. Tests of pancreatic exocrine function - clinical significance in pancreatic and non-pancreatic disorders.
    Keller J; Aghdassi AA; Lerch MM; Mayerle JV; Layer P
    Best Pract Res Clin Gastroenterol; 2009; 23(3):425-39. PubMed ID: 19505669
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Genotype/phenotype correlations and implications for clinical practice.
    Silverberg MS
    J Pediatr Gastroenterol Nutr; 2008 Apr; 46 Suppl 1():E4-5. PubMed ID: 18354327
    [No Abstract]   [Full Text] [Related]  

  • 46. [What can confirm the celiac disease diagnosis?].
    Lamireau T; Clouzeau H
    Arch Pediatr; 2008 Jun; 15(5):504-5. PubMed ID: 18582651
    [No Abstract]   [Full Text] [Related]  

  • 47. [Inflammatory bowel diseases: an immunological approach].
    Sepúlveda SE; Beltrán CJ; Peralta A; Rivas P; Rojas N; Figueroa C; Quera R; Hermoso MA
    Rev Med Chil; 2008 Mar; 136(3):367-75. PubMed ID: 18575665
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effect of probiotics on intestinal barrier function.
    Mennigen R; Bruewer M
    Ann N Y Acad Sci; 2009 May; 1165():183-9. PubMed ID: 19538305
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Multidrug resistance (MDR1) gene in inflammatory bowel disease: a key player?
    Ho GT; Gaya DR; Satsangi J
    Inflamm Bowel Dis; 2005 Nov; 11(11):1013-9. PubMed ID: 16239848
    [No Abstract]   [Full Text] [Related]  

  • 50. Intestinal fibrosis in inflammatory bowel disease: progress in basic and clinical science.
    Rieder F; Fiocchi C
    Curr Opin Gastroenterol; 2008 Jul; 24(4):462-8. PubMed ID: 18622160
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Celiac disease: sandwiched between innate and adaptive immune responses induced by gluten.
    Koning F
    J Pediatr Gastroenterol Nutr; 2008 Apr; 46 Suppl 1():E8-9. PubMed ID: 18354329
    [No Abstract]   [Full Text] [Related]  

  • 52. The significance of gelatin tolerance in malabsorptive states.
    Bronstein HD; Haeffner LJ; Kowlessar OD
    Gastroenterology; 1966 May; 50(5):621-30. PubMed ID: 5935221
    [No Abstract]   [Full Text] [Related]  

  • 53. Use of polyethylene glycol and phenol red as unabsorbed indicators for intestinal absorption studies in man.
    Schedl HP
    Gut; 1966 Apr; 7(2):159-63. PubMed ID: 4160440
    [No Abstract]   [Full Text] [Related]  

  • 54. Proceedings of the World Congresses of Gastroenterology. Vienna, Austria, September 6-11, 1998.
    Dig Dis; 1998; 16(6):327-78. PubMed ID: 10357614
    [No Abstract]   [Full Text] [Related]  

  • 55. [Malabsorption and celiac disease].
    Uscanga L
    Rev Gastroenterol Mex; 2006 Aug; 71 Suppl 1():19-21. PubMed ID: 17037762
    [No Abstract]   [Full Text] [Related]  

  • 56. The genetic puzzle of celiac disease.
    Tursi A
    Gastroenterology; 2004 Apr; 126(4):1216-7; author reply 1217. PubMed ID: 15057768
    [No Abstract]   [Full Text] [Related]  

  • 57. Gastrointestinal permeability in celiac disease.
    Oberhuber G; Vogelsang H
    Gastroenterology; 1998 Jan; 114(1):226. PubMed ID: 9428239
    [No Abstract]   [Full Text] [Related]  

  • 58. Novelties on non-invasive biomarkers for the assessment of intestinal permeability and gut barrier integrity in patients with inflammatory bowel diseases.
    Caviglia GP; Ribaldone DG; Fagoonee S
    Minerva Gastroenterol (Torino); 2023 Mar; 69(1):1-3. PubMed ID: 36856271
    [No Abstract]   [Full Text] [Related]  

  • 59. The gut-skin axis.
    Saarialho-Kere U
    J Pediatr Gastroenterol Nutr; 2004 Jun; 39 Suppl 3():S734-5. PubMed ID: 15167366
    [No Abstract]   [Full Text] [Related]  

  • 60. Interaction between drugs and the gut microbiome.
    Weersma RK; Zhernakova A; Fu J
    Gut; 2020 Aug; 69(8):1510-1519. PubMed ID: 32409589
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.